FDA closes Imricor’s manufacturing module in key PMA milestone
The U.S. Food and Drug Administration (FDA) has completed its evaluation of the manufacturing module within Imricor Medical Systems‘ (ASX: IMR) Premarket Approval (PMA) submission, with the module now accepted and considered closed.
The closure marks another major milestone in Imricor’s modular PMA review with the FDA, advancing the company along the pathway toward US commercial launch of its electrophysiology (EP) platform.
The module covers the design, manufacturing and quality processes surrounding seven products in total, including the Vision-MR® Ablation Catheter and the RF-5000™ Ablation Generator and Pump.
Each closed module de-risks the road to US market entry. Importantly, final approval has not been granted and remains subject to further steps in the review process.
When big ASX news breaks, our subscribers know first
What the manufacturing module covered
Given the number of devices involved, the manufacturing module was described as one of the largest and most complex components of the company’s PMA submission. It encompassed a broad set of processes:
-
Design controls
-
Receipt, inspection and storage of raw materials
-
Build procedures
-
Process validation
-
Part and device traceability
-
Applicable quality management systems
Of the seven products covered, six are the Company’s own products undergoing the FDA’s PMA process, together with a third-party product that Imricor will distribute.
A defining feature of the modular approach is its finality. Once the FDA accepts and closes a module, that module “is not expected to be re-reviewed as part of the final PMA review unless changes are subsequently made to its contents.” This conditional framing means the manufacturing work is effectively locked in, provided its contents remain unchanged.
Understanding the FDA’s modular PMA pathway
A Premarket Approval (PMA) is the FDA’s most stringent review pathway, reserved for high-risk medical devices. It requires manufacturers to demonstrate, through rigorous evidence, that a device is safe and effective before it can be marketed in the United States.
Under a modular review process, a company submits modules covering different aspects of its products, which the FDA then reviews serially. Rather than assessing the entire submission at once at the very end, the regulator evaluates and closes modules one by one.
Why does closing modules progressively matter to investors? Each closure reduces end-stage review risk and provides a visible, verifiable marker of progress toward approval. The table below breaks down the current position and the remaining steps.
| Milestone Step | What It Means | Investor Significance |
|---|---|---|
| Manufacturing module closed | Design, production & quality processes accepted | Major de-risking step |
| Pre-approval inspection (pending) | FDA to inspect manufacturing sites | Required before approval |
| Final PMA approval (pending) | All modules + inspection satisfied | Unlocks US launch |
CEO frames milestone as validation of quality systems
Imricor’s Chair and CEO, Steve Wedan, characterised the module closure as a strong endorsement of the systems his team has built.
Steve Wedan, Chair and CEO
“Manufacturing is one of the most demanding components of any PMA, and ours covered seven devices at once. To have the FDA complete its evaluation and close this module is a strong validation of the design controls, production processes and quality system our team has built. It is the kind of milestone that is easy to state in a sentence but very hard to earn.”
Wedan added that the company continues to progress through both 510(k) and PMA processes across a broad portfolio of electrophysiology devices to support the commercial launch of its EP platform in the United States. “Every closed module brings us a step closer to delivering iMR-guided EP to U.S. physicians and their patients,” he said.
The NorthStar 510(k) clearance, granted in early 2026, established Imricor as the holder of the first and only FDA-cleared MRI-native 3D cardiac mapping system in the US, running alongside the PMA track as a parallel commercialisation pathway.
What’s next on the road to US approval
Prior to any final PMA approval, the FDA will conduct a pre-approval inspection of the Company’s manufacturing sites. This inspection remains an outstanding requirement before the device can reach the US market.
Final approval remains subject to the FDA’s satisfactory completion of its review of all modules and the pre-approval inspection. The announcement does not disclose any timeline or dates for these remaining steps.
Imricor already holds a regulatory footprint elsewhere. Its products are approved in the European Union, the Kingdom of Saudi Arabia and New Zealand, while the NorthStar® Mapping System and the Vision-MR Diagnostic Catheter are cleared in the US.
For investors, the US PMA pathway represents the key value-unlock catalyst for the company. With the manufacturing module now closed, the remaining route to US approval narrows to two clearly identifiable hurdles: the completion of the FDA’s review of all modules, and the pre-approval site inspection.
Investors exploring how the approved NorthStar system has already begun generating US revenue will find our detailed coverage of Imricor’s first US hospital sale informative, including the scale of projected revenue relative to the company’s entire 2025 European business and the addressable market opened by dual pediatric label expansions in July 2026.
Don’t Miss the Next ASX Healthcare Milestone
Get FREE breaking ASX healthcare news delivered to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ investors already staying ahead of the market with Big News Blast. Click the “Free Alerts” button to receive the next market-moving update the moment it hits the ASX.